凉血活血胶囊治疗血热型银屑病的临床研究

目的观察凉血活血胶囊治疗血热型银屑病的临床疗效。方法采用随机、单盲、对照法。结果凉血活血胶囊可显著改善患者皮损体征,并在一定程度上优于复方青黛胶囊。凉血活血胶囊组总有效率为62.5%,虽优于复方青黛胶囊组,但无统计学差异(P>0.05)。同时,凉血活血胶囊可显著改善患者皮肤瘙痒、口干舌燥、心烦易怒、大小便异常等临床伴随症状,并在一定程度上优于复方青黛胶囊。结论凉血活血胶囊治疗血热型银屑病有较好的疗效。     

凉血解毒消风药治疗血热型银屑病的临床疗效与安全性

目的探讨凉血解毒消风药治疗血热型银屑病的临床疗效与安全性。方法选取2013年8月-2015年12月在我院皮肤科就诊的血热型银屑病患者120例,随机均分为治疗组与对照组,治疗组采用凉血解毒消风药煎汤内服,对照组给予复方青黛胶囊口服;比较两组患者治疗前后PASI总分、临床疗效及不良反应发生情况。结果两组患者治疗后PASI总分均显著低于治疗前(P0.05),且治疗组显著低于对照组(P0.05)。治疗组总有效率78.33%(47/60),显著高于对照组的60.00%(36/60)(P0.05)。治疗后患者不良反应发生率分别为:治疗组10.00%(6/60)、对照组5.00%(3/60),其中稀便为主要不良反应,两组比较差异无统计学意义(P0.05)。两组患者治疗前后血常规、肝肾功指标比较差异均无统计学意义(p0.05)。结论采用凉血解毒消风药治疗血热型银屑病疗效确切,且具有较好的安全性,临床疗效优于复方青黛胶囊。     

凉血消风汤联合阿维A治疗银屑病血热型34例临床疗效观察

目的观察凉血消风汤联合阿维A治疗银屑病血热型疗效观察。方法将34例银屑病患者随机分为2组,每组17例,对照组予以口服阿维A,1次/d;治疗组予以口服阿维A加凉血消风汤治疗。比较2组的疗效差异。结果 2组治疗前银屑病损面积和严重程度指数(PASI)评分比较差异无统计学意义(P0.05),治疗后2组PASI评分差异有统计学意义(P0.05),治疗组治疗前后比较PASI评分差异有统计学意义(P0.05);2组临床疗效对比差异有统计学意义(P0.05)。结论凉血消风汤联合阿维A治疗银屑病血热型疗效确切,值得临床推广。     

凉血消银方结合阿维A胶囊治疗对寻常型银屑病(血热症)外周血T细胞亚群Th17调控作用的研究

目的 探讨凉血消银方结合阿维A胶囊治疗对寻常型银屑病(血热症)外周血T细胞亚群辅助性T细胞17(Th17)调控作用.方法 选择2016年5月—2018年5月我院收治的寻常型银屑病患者98例,根据随机对照法将患者分为治疗组和对照组,每组49例.对照组患者口服阿维A胶囊治疗,治疗组在对照组治疗的基础上,口服凉血消银汤治疗....     

紫草素、靛玉红对角质形成细胞凋亡的影响

目的：探讨凉血活血胶囊(liangcuehuoxue capsule)治疗银屑病的机制。方法：采用流式细胞仪分析细胞亚二倍体含量和Annexin V法分析细胞PS膜外化含量，观察凉血活血胶囊及其主要组成药物的主要成分紫草素(shikomn)、靛玉红(indirubin)对角质形成细胞凋亡的影响。结果：一定浓度的凉血活血胶囊及紫草素、靛玉红可诱导角质形成细胞凋亡。结论：诱导细胞凋亡可能是中药凉血活血胶囊治疗银屑病的作用机制之一。     

凉血消风汤对血热型寻常性银屑病患者外周血淋巴细胞乙酰化内稳态的影响

目的探讨血热型银屑病患者外周血单个核细胞组蛋白乙酰化酶(HATs)和去乙酰化酶(HDACs)的关系;研究凉血消风汤对HATs和HDACs平衡的影响,从而揭示银屑病乙酰化内稳态的变化。方法收集寻常性血热型银屑病患者,设立中药治疗组和健康对照组,治疗组给予凉血消风汤6g,2次/d,治疗4周后,采用酶联免疫吸附法分别测定治疗前后血清中TNF-α含量,PBMC提取组蛋白后应用组蛋白乙酰化酶活性和去乙酰化酶活性试剂盒测定组蛋白HATs和HDACs水平。结果银屑病患者治疗后血清中TNF-α表达降低(P0.05),HATs表达上升(P0.05),HDACs表达降低(P0.05),差异均有统计学意义。结论凉血消风汤能够降低银屑病患者血清TNF-α含量,从而治疗银屑病,其机制可能与调节乙酰化内稳态平衡有关。     

凉血解毒饮对血热型银屑病患者生活质量及P物质水平的影响

目的探讨自拟方凉血解毒饮对于血热型银屑病患者生活质量的影响及与P物质水平的关系。方法选择180例血热型银屑病患者,随机分为治疗组(凉血解毒饮组)和对照组(消银颗粒),每组90例,两组均外用卡泊三醇软膏,根据皮肤病生活质量指数(DLQI)、PASI评分方法判定疗效及对患者生活质量的影响程度,以双抗夹心ELISA方法来评定药物对P物质的影响及其相关性。结果治疗组疗效明显优于对照组,改善了患者的生活质量,且与P物质水平呈正相关。结论凉血解毒饮对血热型银屑病有一定的疗效,有效改善了患者的生活质量,与P物质水平的变化可能有关联。     

清热凉血解毒汤治疗血热型寻常性银屑病疗效及对外周血炎症因子的影响

目的探讨清热凉血解毒汤治疗血热型寻常性银屑病的临床疗效及对外周血炎症因子的影响。方法选取我院2014年6月-2016年7月收治的108例血热型寻常性银屑病患者,采取随机数字表将其分成两组,每组54例。两组患者均给予常规西药治疗,观察组加用清热凉血解毒汤治疗,比较两组临床疗效、治疗前后银屑病面积与严重性指数(PASI)评分、主要证候积分、外周血炎症因子水平以及生活质量变化情况。结果观察组治疗总有效率为92.59%,与对照组(66.67%)相比有明显上升(P0.01)。两组治疗后PASI评分与治疗前比较有显著下降(P0.01)。两组患者治疗后瘙痒、红斑、心烦、口干口渴积分均较治疗前有明显下降(P0.01),观察组治疗后各项主要证候积分均明显低于对照组治疗后(P0.01)。两组患者治疗后生理状态、日常活动、心理状态、社交娱乐评分均较治疗前有明显下降(P0.01)。两组患者治疗后血清IL-6,IL-8,TNF-α水平均明显低于治疗前(P0.01)。结论清热凉血解毒汤治疗血热型寻常性银屑病可有效缓解临床症状、减轻机体炎症反应,疗效确切。     

回药活血消疕胶囊治疗寻常型银屑病血瘀证123例疗效观察

目的观察回药活血消疕胶囊治疗寻常型银屑病血瘀证临床疗效,探讨其作用机制。方法将寻常型银屑病血瘀证患者132例,随机分为2组,除去脱落病例,即治疗组61例、对照组62例。治疗组给予活血消疕胶囊口服;对照组给予雷公藤多苷片口服,2组均外擦医用凡士林,疗程12周。对2组前后银屑病皮损面积和严重程度指数(PASI)评分、红斑、鳞屑、浸润程度进行评价,检测治疗前后肝肾功能,临床痊愈患者于治疗结束后第6、12个月进行随访。结果活血消疕胶囊经临床研究表明在治疗12周后与治疗前PASI积分比较,治疗组PASI积分低于对照组,差异有统计学意义(P0.05)。2组12周后进行比较,治疗组和对照组总有效率分别为83.61%、64.52%,治疗组总有效率高于对照组,2组总疗效有统计学意义(P0.05)。随访1年复发率比较,治疗组和对照组复发率分别为13.1%、24.2%,说明治疗组复发率明显低于对照组,差异有统计学意义(P0.05)。结论活血消疕胶囊治疗寻常型银屑病血瘀证,通过对PASI评分、在改善红斑、鳞屑、浸润、防止复发方面疗效显著,其作用机制可能与提高机体免疫力有关,为临床治疗寻常型银屑病血瘀证提供了初步临床依据,开展了新药的临床研究。     

凉血活血胶囊对皮肤角质形成细胞凋亡的研究

目的 观察凉血活血胶囊对体外角质形成细胞株凋亡的影响,初步探讨其治疗银屑病的机制。方法 以TUNEL法检测银屑病患者皮损细胞凋亡、PCNA检测增殖细胞核抗原,并以碘化丙啶法和膜联蛋白V法在流式细胞仪上检测凉血活血胶囊对体外角质形成细胞凋亡作用的影响。结果 银屑病皮损中基底层和棘细胞中下层角质形成细胞增殖和凋亡较正常皮肤均有所增加。凉血活血胶囊可诱导培养的角质形成细胞凋亡,在1、5、10 mg/mL时分别为24.67±5.07、50.33±10.04、66.20±6.91,随着浓度增加,细胞凋亡率增加,与正常对照组比较差异有显著性,与试验对照复方青黛胶囊组比较差异无显著性。结论 银屑病皮损中角质形成细胞增殖和凋亡发生紊乱,两者在较高水平保持相对平衡。凉血活血胶囊可以诱导细胞凋亡,从而达到治疗银屑病的目的。     

Botulinum toxin A in the treatment of the wrinkles in the upper third of the face

The practice of botulinum toxin injections is unavoidable in the correction of facial aging. In effect botulinum toxin allows to erase dynamic wrinkles, by transient and reversible muscular relaxation. This is the best wrinkle treatment for the upper part of the face: glabellar lines, horizontal forehead lines and crow's feet. This technique requires a good understanding of facial muscular anatomy, in order to correctly apply the basics of injection. Every patient is unique and only a big experience will allow to refine and personalise injections.     

Changes in the T-wave of the electrocardiograph in urticaria

A series of cases is presented, in which non-specific primary changes in the T-waves were observed in electrocardiographs of patients with urticaria, the latter caused by drugs or other substances. In all these patients, no other abnormality was found and they were completely asymptomatic as regards cardiac involvement. A definite ‘cause and effect’ type of relationship was found between the T-wave changes and the urticaria. The mechanism of the T-wave changes remains to be investigated. Since this phenomenon disappears simultaneously with the urticaria, treatment should be determined by the urticaria, and bed rest is not indicated.     

Ultrastructure of the Fibrous Substance in the Keratinocytes of the Epidermis in Healthy Individuals

The present findings in the epidermis of healthy individuals suggest that the fibrous substance in the keratinocytes is subjected to an individual differentiation as the cells move from stratum basale through strata spinosum and intermedium to stratum coreum. In the basal cells the fibrous substance consists of opaque tonofilaments, mostly aggregated in dense tonofibrils, but also occurring randomly scattered and in loose tonofibrils (fibrous substance of basal-cell type). In most cells the fibrous substance undergoes differentiation: a) in stratum spinosum into compact tonofibrils with no individual tonofilaments visible (fibrous substance of spinous-cell type), b) in stratum inter-medium into compact tonofibrils with intensely stained regions or keratohyalin (fibrous substance of intermediate-cell type), and c) in stratum corneum into tonofibrils with a keratin pattern (fibrous substance of horny-cell type). There are also keratinocytes in which the fibrous substance undergoes only an incomplete differentiation, with the appearance of horny cells with a fibrous substance of spinous-cell type, intermediate-cell type or horny-cell type with keratohyalin. Finally, there are keratinocytes in which the fibrous substance does not undergo any differentiation at all, but which display a fibrous substance of basal-cell type throughout the entire epidermis.     

Experience in the use of ditrastic in the therapy of psoriasis

Forty-six patients suffering from psoriasis have been treated with ditrastic, a new drug for external application, manufactured by Orion, Finland. The drug is manufactured in the form of sticks weighing 2.4 g, containing 1.5 or 3% of dithranol, paraffin, and microcrystalline sulfur. These sticks are applied to psoriatic plaques once daily. The treatment has been effective.